A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. - Desai,A.A.; Vogelzang,N.J.; Rini,B.I.; Ansari,R.; Krauss,S.; Stadler,W.M. (Cancer, 2002)